new_0222_0621|TLIS|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0621|TLIS|1|Talis Biomedical Corp Total Current Assets (Quarterly) (USD)|Talis Biomedical Corp Cash and Short Term Investments (Quarterly) (USD)|Talis Biomedical Corp Inventories (Quarterly) (USD)|Talis Biomedical Corp Net PP&E (Quarterly) (USD)|Talis Biomedical Corp Goodwill and Intangibles (Quarterly) (USD)|Talis Biomedical Corp Total Liabilities (Quarterly) (USD)|Talis Biomedical Corp Total Current Liabilities (Quarterly) (USD)|Talis Biomedical Corp Total Long Term Liabilities (Quarterly) (USD)|Talis Biomedical Corp Total Deposits (Quarterly) (USD)|Talis Biomedical Corp Book Value (Quarterly) (USD)|Talis Biomedical Corp Retained Earnings (Quarterly) (USD)|Talis Biomedical Corp Treasury Stock (Quarterly) (USD)|Talis Biomedical Corp EV to Revenues|Talis Biomedical Corp EV to Earnings|Talis Biomedical Corp EV to Free Cash Flow|Talis Biomedical Corp EV to Assets (Quarterly)|Talis Biomedical Corp PS Ratio|Talis Biomedical Corp PE Ratio|Talis Biomedical Corp Price to Book Value|Talis Biomedical Corp PEG Ratio|Talis Biomedical Corp Debt to Equity Ratio|Talis Biomedical Corp Dividend Yield|Talis Biomedical Corp Shareholder Yield (TTM)|Talis Biomedical Corp Percent of Shares Outstanding Short|Talis Biomedical Corp Total Receivables (Quarterly) (USD)|Talis Biomedical Corp Total Payables (Quarterly) (USD)|Talis Biomedical Corp Total Capital Stock (Quarterly) (USD)|Talis Biomedical Corp Return on Invested Capital|Talis Biomedical Corp Quality Ratio Score|Talis Biomedical Corp Momentum Score|Talis Biomedical Corp Beta (1Y)|Talis Biomedical Corp Sustainable Growth Rate (TTM)|Talis Biomedical Corp Institutional Investor Ownership Percentage|Talis Biomedical Corp Average Diluted Shares Outstanding (Quarterly)|Talis Biomedical Corp Total Employees (Annual)|Talis Biomedical Corp EPS Diluted (Quarterly) (USD)|Talis Biomedical Corp SG&A Expense (Quarterly) (USD)|Talis Biomedical Corp Shares Outstanding|Talis Biomedical Corp Repurchase of Capital Stock (Quarterly) (USD)|Talis Biomedical Corp Ordinary Shares Number (Quarterly)|Talis Biomedical Corp Payout Ratio|Talis Biomedical Corp Quick Ratio (Quarterly)|Talis Biomedical Corp Normalized Diluted EPS (Quarterly) (USD)|Talis Biomedical Corp Stock Buybacks (Quarterly) (USD)|Talis Biomedical Corp Effective Tax Rate (TTM)|Talis Biomedical Corp Return on Equity|Talis Biomedical Corp Net Income (TTM) (USD)|Talis Biomedical Corp Revenue (TTM) (USD)|Talis Biomedical Corp Dividend Per Share (Quarterly) (USD)|Talis Biomedical Corp Revenue (Quarterly) (USD)|Talis Biomedical Corp Gross Profit (Quarterly) (USD)|Talis Biomedical Corp Pre-Tax Income (Quarterly) (USD)|Talis Biomedical Corp Net Income (Quarterly) (USD)|Talis Biomedical Corp Net Interest Income (Quarterly) (USD)|Talis Biomedical Corp Price (USD)|Talis Biomedical Corp Total Return Price (USD)|Talis Biomedical Corp Enterprise Value (USD)|Talis Biomedical Corp 30-Day Average Daily Volume|Talis Biomedical Corp 1 Year Price Returns (Daily)|Talis Biomedical Corp Short Interest|Talis Biomedical Corp PE Ratio (Forward)|Talis Biomedical Corp PE Ratio (Forward 1y)|Talis Biomedical Corp PS Ratio (Forward)|Talis Biomedical Corp PS Ratio (Forward 1y)|Talis Biomedical Corp Quarterly EPS Estimates (USD)|Talis Biomedical Corp Quarterly Revenue Estimates (USD)|Talis Biomedical Corp Quarterly EPS Surprise|Talis Biomedical Corp Quarterly Revenue Surprise|Talis Biomedical Corp Quarterly Actual EPS (USD)|Talis Biomedical Corp Quarterly Actual Revenue (USD)|Talis Biomedical Corp Revenue Estimates for Current Fiscal Year (USD)|Talis Biomedical Corp Revenue Estimates for Next Fiscal Year (USD)|Talis Biomedical Corp Price Target (USD)|Talis Biomedical Corp Consensus Recommendation|Talis Biomedical Corp Price Target Num Estimates|Talis Biomedical Corp EPS Estimates for Current Fiscal Year (USD)|Talis Biomedical Corp EPS Estimates for Next Fiscal Year (USD)|Talis Biomedical Corp Research and Development Expense (Quarterly) (USD)|Talis Biomedical Corp Reconciled Depreciation (Quarterly) (USD)|Talis Biomedical Corp Non-Operating Interest Expense (Quarterly) (USD)|Talis Biomedical Corp Land and Improvements (Quarterly) (USD)|Talis Biomedical Corp Buildings and Improvements (Quarterly) (USD)|Talis Biomedical Corp Other Properties (Quarterly) (USD)|Talis Biomedical Corp Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0621|TLIS|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0621|TLIS|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|monthly|quarterly|quarterly|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0621|TLIS|5|127.8|127.8||127.8||127.8|127.8|127.8||127.8|127.8||||1.44357976654||||1.44|||1.44357976654||15.347826087|127.8|127.8|127.8||||||30.6363636364|91.2857142857||91.2857142857|91.2857142857|30.5555555556||127.8|||91.2857142857|91.3333333333|||91.25|||||91.2857142857|91.2857142857||1.44357976654|1.44357976654|1.44357976654|1.44298245614|1|15.347826087|||1.44357976654|1.44357976654|91.25|91.25|91|91|91|91|24.8|22.9090909091|25.3333333333|21.7142857143|25.3333333333|26.5714285714|25.2|91.2857142857|91.2857142857||||127.8|183||
new_0222_0621|TLIS|6|5|5||5||5|5|5||5|5||||257||||225|||257||23|5|5|5||||||11|7||7|7|9||5|||7|6|||4|||||7|7||257|257|257|228|4|23|||257|257|8|8|3|3|3|3|15|11|12|14|12|14|10|7|7||||5|2||
new_0222_0621|TLIS|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0621|TLIS|201912|24.107|21.604||1.535||46.873|4.037|42.836||-21.14|-81.776||||||||||||||1.806|1.566||||||||4.3603||-1.7512|1.764|||19.6799|||-1.7512|||||||||-7.636|-7.636|0.044||||||||||||||||||||||||6.946|0.187||||2.293|0.663||
new_0222_0621|TLIS|202003||||||||||||||||||||||||||||||||||4.3603||-1.6912|2.08||||||-1.6912|||||||||-7.374|-7.374|||||||||||||||||||||||||5.714|0.185|||||||
new_0222_0621|TLIS|202006||||||||||||||||||||||||||||||||||4.3603||-2.304|2.66||||||-2.304|||||||||-10.046|-10.046|||||||||||||||||||||||||8.184|0.193|||||||
new_0222_0621|TLIS|202009|106.004|55.406||9.157||181.194|13.717|167.477||-65.942|-128.71||||||||||||||0.334|3.958||||||||4.3603||-6.7688|3.058|||19.6799|||-6.7688||||-54.57|||||-29.514|-29.514|||||||||||||||||||||||||36.011|0.186||||3.915|0.83||
new_0222_0621|TLIS|202012|188.724|138.483||9.681||306.976|16.026|290.95||-108.571|-172.906||||-3.1924|||||||||3.5558|0.471|4.906|||||||4.3816|19.6799|136|-2.2457|5.305|25.6362||19.6799|||-2.2457||||-91.13|||||-44.196|-44.196||17.26|17.26|303.9978|||911572|||52.1179|12.6305|-0.77|0.2334|-3470.1299|-0.1628|-27.49|0.233|10.9381|||||-11.52||39.11|0.199||||4.441|0.848||
new_0222_0621|TLIS|202103|391.322|348.012||10.112||46.849|46.849|||356.33|-233.398||||0.1647||||0.9245|||||9.1811||10.826|0.005|||||||13.1107||-4.61|7.327|25.6376||25.6376|||-4.61|-233.348|||-144.248|||||-60.492|-60.492||12.85|12.85|-18.5658|405883||2353813|||38.8037|9.4039|-0.7828|5.375|-488.9116|30.2326|-4.61|7|72.051|119.5488|16.75|2|4|-1.47|-1.3809|60.193|0.216||||10.112||12|9.74
new_0222_0621|TLIS|202106|353.865|313.458||23.925||85.806|72.629|13.177||293.729|-297.87||||0.2239||||0.9647|||||7.0434|0.117|11.695|0.005||||||97.5054|25.6482||-2.51|9.983|25.6904||25.6904|||-2.51|0.802|||-198.674|||||-64.472|-64.472||11.03|11.03|-30.0899|273422.3||1809468|||33.3763|8.0886|-0.9113||-175.4428||-2.51|0.117|10.2198|65.563|9.6667|3|3|-7.3084|-2.4769|54.495|0.194||||23.925||10.3|8.06
new_0222_0621|TLIS|202109|277.557|273.603||23.791||44.304|31.342|12.962||258.789|-336.288||||0.6487||||0.627|||||5.3478|0.219|5.388|0.005||||||70.3646|25.7871||-1.49|12.792|25.963||25.963|||-1.49||||-207.578|||||-38.418|-38.418||6.25|6.25|-111.3312|237996.3667||1388457|||19.1129|4.6319|-1.3985|1.4613|-6.5458|-85.0817|-1.49|0.218|11.2541|61.8766|8.5|3.3333|2|-8.0046|-3.2682|25.841|0.231||||23.791||5.35|4.68
new_0222_0621|TLIS|202112|||||||||||||||0.98||||0.4073|||||2.909|||||||||68.1939||||||||||||||||||||||4.01|4.01|-168.1827|217257.1333|-91.5884|764729|||3.0091|1.4801|-1.284|1.3333|||||8.49||4.5|3.6667|2|-8.3362|||||||||2.95|2.06
new_0222_0621|TLIS|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-1.23|1.2||||||||||||||||||||
new_0222_0621|TLIS|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-1.195|4||||||||||||||||||||
new_0222_0621|TLIS|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-1.12|6.3||||||||||||||||||||
new_0222_0621|TLIS|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.935|28.5||||||||||||||||||||